Per accedir als documents amb el text complet, si us plau, seguiu el següent enllaç: http://hdl.handle.net/2445/147217
dc.contributor.author | Montal, Robert |
---|---|
dc.contributor.author | Andreu Oller, Carmen |
dc.contributor.author | Bassaganyas, Laia |
dc.contributor.author | Esteban Fabró, Roger |
dc.contributor.author | Moran, Sebastian |
dc.contributor.author | Montironi, Carla |
dc.contributor.author | Moeini, Agrin |
dc.contributor.author | Pinyol, Roser |
dc.contributor.author | Peix, Judit |
dc.contributor.author | Cabellos, Laia |
dc.contributor.author | Villanueva, Augusto |
dc.contributor.author | Sia, Daniela |
dc.contributor.author | Mazzaferro, Vincenzo |
dc.contributor.author | Esteller, Manel |
dc.contributor.author | Llovet i Bayer, Josep Maria |
dc.date | 2020-01-08T08:39:32Z |
dc.date | 2020-01-08T08:39:32Z |
dc.date | 2019-07-09 |
dc.date | 2020-01-08T08:33:03Z |
dc.identifier | 695388 |
dc.identifier | 5706249 |
dc.identifier.uri | http://hdl.handle.net/2445/147217 |
dc.description | The clinical utility of serum alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma (HCC) is widely recognised. However, a clear understanding of the mechanisms of AFP overexpression and the molecular traits of patients with AFP-high tumours are not known. We assessed transcriptome data, whole-exome sequencing data and DNA methylome profiling of 520 HCC patients from two independent cohorts to identify distinct molecular traits of patients with AFP-high tumours (serum concentration?>?400?ng/ml), which represents an accepted prognostic cut-off and a predictor of response to ramucirumab. Those AFP-high tumours (18% of resected cases) were characterised by significantly lower AFP promoter methylation (p?0.001), significant enrichment of progenitor-cell features (CK19, EPCAM), higher incidence of BAP1 oncogene mutations (8.5% vs 1.6%) and lower mutational rates of CTNNB1 (14% vs 30%). Specifically, AFP-high tumours displayed significant activation of VEGF signalling (p?0.001), which might provide the rationale for the reported benefit of ramucirumab in this subgroup of patients. |
dc.format | 3 p. |
dc.format | application/pdf |
dc.language | eng |
dc.publisher | Nature Publishing Group |
dc.relation | Reproducció del document publicat a: https://doi.org/10.1038/s41416-019-0513-7 |
dc.relation | British Journal of Cancer, 2019, vol. 121, p. 340–343 |
dc.relation | https://doi.org/10.1038/s41416-019-0513-7 |
dc.relation | info:eu-repo/grantAgreement/EC/H2020/667273/EU//HEP-CAR |
dc.rights | (c) Montal et al., 2019 |
dc.rights | info:eu-repo/semantics/openAccess |
dc.subject | Càncer de fetge |
dc.subject | Oncogènesi |
dc.subject | Liver cancer |
dc.subject | Carcinogenesis |
dc.title | Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/publishedVersion |